H.C. Wainwright reiterated a Buy rating on shares of GH Research PLC (NASDAQ:GHRS), with a price target of $40.00. Currently ...
A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...
A groundbreaking study by researchers from Mass General Brigham and Washington University School of Medicine in St. Louis has ...
Brighton and Sussex Medical School and Royal Sussex County Hospital researchers have published an analysis of Francis ...
In a paper recently published in the leading journal "The Lancet Digital Health", a scientific team led by Stanisa Raspopovic from MedUni Vienna looks at the progress and challenges in the research ...
A scientific team looks at the progress and challenges in the research and development of brain implants. New achievements in the field of this technology are seen as a source of hope for many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback